On August 28, 2020, the investigator meeting for the Phase IIa clinical trial of "Recombinant Human Thymosin β4 for Injection (NL005)," hosted by Beijing Northland Biotechnology Co., Ltd., was successfully held at the Guobin Hotel in Beijing. More than 30 participants attended the meeting, including medical experts from the leading center—the Fuwai Hospital of the Chinese Academy of Medical Sciences—as well as from four research centers: Beijing Luhe Hospital affiliated with Capital Medical University, Beijing Chaoyang Hospital affiliated with Capital Medical University, Tianjin Medical University General Hospital, and TEDA International Cardiovascular Hospital, along with relevant personnel from third-party research organizations such as Lianshida and Taimi Medical.

　　The meeting was chaired by Director Dou Kefei, the principal investigator of the Phase II clinical trial and Director of the Department of Cardiology at Fuwai Hospital, Chinese Academy of Medical Sciences. First, Han Chengquan, Vice President of the company, provided an overview of the company’s background and the development progress of NL005. Subsequently, medical personnel presented the research background of the investigational drug as well as preliminary research findings. The project manager then explained the project management plan. Representatives from the participating research institutions gave detailed introductions on topics including MRI imaging procedures involved in the trial, safety event management protocols, and the roles and responsibilities of SMO staff. All participants engaged in a lively discussion on key aspects such as the clinical trial protocol, trial methodology, and requirements, ultimately reaching a consensus.

　　Han Chengquan, Vice President of the company, stated: “Recombinant Human Thymosin β4 for Injection is an innovative Class 1 drug developed by our company. It is a key new drug development project under the nation’s 13th Five-Year Plan, and its trial protocol presents certain challenges. If successfully developed, this drug will offer a new therapeutic solution for clinical treatment of reperfusion injury caused by acute myocardial infarction, holding significant social importance. We hope that all researchers will conduct the trials in a standardized manner, and our company will provide robust support to ensure the smooth implementation of these trials.”

　　The successful convening of this researchers’ meeting marks the official and comprehensive launch of the Phase IIa clinical trial for “Recombinant Human Thymosin β4 for Injection.” The company will mobilize and effectively allocate resources from all relevant parties, perform robust project management, and ensure that the trial is conducted scientifically, rigorously, and in compliance with established standards, as scheduled.